NASDAQ:CRBP

Corbus Pharmaceuticals - CRBP Stock Forecast, Price & News

$0.12

0.00 (0.00%)

(As of 12/9/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.12
▼
$0.13
50-Day Range: $0.11
▼
$0.19
52-Week Range: $0.10
▼
$0.82

Volume: 977,499 shs
Average Volume: 2.25 million shs
Market Capitalization: $15.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Corbus Pharmaceuticals MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
3.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.65
Upright™ Environmental Score
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.25) to ($0.31) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.50 out of 5 stars

Medical Sector

945th out of 1,034 stocks

Pharmaceutical Preparations Industry

456th out of 504 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Corbus Pharmaceuticals.

4.0

Short Interest

Percentage of Shares Shorted
3.71% of the float of Corbus Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Corbus Pharmaceuticals has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Corbus Pharmaceuticals has recently decreased by 2.52%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Corbus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Corbus Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Corbus Pharmaceuticals has received a 73.92% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Corbus Pharmaceuticals is -0.65.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Corbus Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
17 people have searched for CRBP on MarketBeat in the last 30 days. This is an increase of 113% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corbus Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.20% of the stock of Corbus Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 25.40% of the stock of Corbus Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($0.25) to ($0.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corbus Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corbus Pharmaceuticals is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Corbus Pharmaceuticals has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Stock News Headlines

December 4, 2022 | americanbankingnews.com

StockNews.com Begins Coverage on Corbus Pharmaceuticals (NASDAQ:CRBP)

November 10, 2022 | finance.yahoo.com

Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

November 8, 2022 | finance.yahoo.com

Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

October 25, 2022 | msn.com

Why Qualtrics International Shares Are Trading Sharply Higher; Here Are 23 Stocks Moving Premarket

October 14, 2022 | finance.yahoo.com

Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

September 26, 2022 | finance.yahoo.com

Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors

September 22, 2022 | finance.yahoo.com

Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference

September 12, 2022 | finance.yahoo.com

Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference

August 9, 2022 | finance.yahoo.com

Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 6, 2022 | finance.yahoo.com

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

May 10, 2022 | apnews.com

Corbus Pharmaceuticals: Q1 Earnings Snapshot

May 10, 2022 | seekingalpha.com

Corbus Pharmaceuticals GAAP EPS of -$0.08 beats by $0.01

May 10, 2022 | markets.businessinsider.com

Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

April 18, 2022 | msn.com

Marijuana Stock Movers For April 18, 2022

April 8, 2022 | finance.yahoo.com

Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting

April 7, 2022 | marketwatch.com

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors

April 7, 2022 | msn.com

Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study

April 5, 2022 | msn.com

Cannabis Stock Gainers And Losers From April 5, 2022

April 4, 2022 | marketwatch.com

Corbus Pharmaceuticals Holdings Inc. stock falls Monday, underperforms market

March 11, 2022 | finance.yahoo.com

Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

March 8, 2022 | benzinga.com

Corbus Pharmaceuticals: Q4 Earnings Insights

March 8, 2022 | finance.yahoo.com

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates

March 2, 2022 | finance.yahoo.com

Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

February 15, 2022 | benzinga.com

Clever Leaves Expands Deal With Cannatrek In Australia Via $3.6M Sales Agreement To Include THC Flower

February 2, 2022 | msn.com

Cannabis Stock Gainers And Losers From February 2, 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Company Calendar

Last Earnings: 11/12/2021
Today: 12/10/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/14/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CRBP
CUSIP: N/A
CIK: 1595097
Web: www.corbuspharma.com
Phone: (617) 963-0100
Fax: 617-663-6085
Employees: 41
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-45,640,000.00
Net Margins: N/A
Pretax Margin: -36,209.27%
Return on Equity: -66.27%
Return on Assets: -40.89%

Debt

Debt-to-Equity Ratio: 0.22
Current Ratio: 3.86
Quick Ratio: 3.86

Sales & Book Value

Annual Sales: $880,000.00
Price / Sales: 17.67
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.55 per share
Price / Book: 0.23

Miscellaneous

Outstanding Shares: 125,281,000
Free Float: 115,008,000
Market Cap: $15.55 million
Optionable: Optionable
Beta: 1.93

Key Executives

Dr. Yuval Cohen Ph.D. (Age 47)
CEO & Director
Comp: $846.92k

Mr. Sean F. Moran CPA (Age 64)
M.B.A., CPA, MBA, Chief Financial Officer
Comp: $542k

Mr. Craig Stuart Millian M.B.A. (Age 53)
Chief Operating Officer
Comp: $542k

Dr. Rachael Brake Ph.D. (Age 50)
Chief Scientific Officer

Ted Jenkins
Sr. Director of Investor Relations & Corp. Communications

Ms. Lindsey Smith
Head of Corp. Communications & Patient Advocacy

Ms. Christina Bertsch
Head of HR

Scott Constantine
Sr. Director & Head of Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CRBP Stock - Frequently Asked Questions

How have CRBP shares performed in 2022?: Corbus Pharmaceuticals' stock was trading at $0.6157 at the beginning of 2022. Since then, CRBP stock has decreased by 79.8% and is now trading at $0.1241.
View the best growth stocks for 2022 here.
When is Corbus Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our CRBP earnings forecast.
How were Corbus Pharmaceuticals' earnings last quarter?: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its quarterly earnings data on Friday, November, 12th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.10. The biopharmaceutical company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.81 million.
What other stocks do shareholders of Corbus Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?: Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."
Who are Corbus Pharmaceuticals' major shareholders?: Corbus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ETF Managers Group LLC (3.76%), Vanguard Group Inc. (3.23%), Pinnacle Associates Ltd. (0.66%), Renaissance Technologies LLC (0.63%), ExodusPoint Capital Management LP (0.29%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Barbara White, Craig Stuart Millian, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends.
How do I buy shares of Corbus Pharmaceuticals?: Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Corbus Pharmaceuticals' stock price today?: One share of CRBP stock can currently be purchased for approximately $0.12.
How much money does Corbus Pharmaceuticals make?: Corbus Pharmaceuticals (NASDAQ:CRBP) has a market capitalization of $15.55 million and generates $880,000.00 in revenue each year. The biopharmaceutical company earns $-45,640,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.
How can I contact Corbus Pharmaceuticals?: Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The official website for the company is www.corbuspharma.com. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at ir@corbuspharma.com, or via fax at 617-663-6085.

This page (NASDAQ:CRBP) was last updated on 12/10/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial